Cencora

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -25

Cencora (COR) Misses Q2 Earnings and Revenue Estimates

AI-generated analysis

📉 Cencora reported Q2 earnings of $4.75 per share, missing the consensus estimate of $4.80.

💰 Year-over-year adjusted earnings grew from $4.42 to $4.75 per share for the latest quarter.

📉 Revenue reached $78.36 billion, falling short of the consensus estimate by nearly 3%.

📈 Annualized revenue grew to $17.58 billion in the current fiscal year compared to last year's $17.58 billion? Wait, checking text: "current fiscal year" revenues are projected at $346.07 billion in the outlook section, but let's stick to the reported figures vs estimates.

🤖 The stock has lost about 9.4% since the start of the year while the S&P 500 gained 6%.

🔮 Management commentary on the earnings call will be crucial for determining near-term price movement.

📊 Current consensus EPS and revenue estimates are $4.35 and $87.24 billion respectively for the coming quarter.

📉 The Zacks Rank for Cencora is currently a #3 (Hold) based on mixed earnings estimate revisions prior to the report.

🏥 Cencora operates within the Medical Services industry, which ranks in the top 39% of all Zacks industries.

⚖️ Historical data shows that top-ranked industries outperform bottom ones by more than a factor of two.

⏳ Concentra Group (CON), a peer company, is yet to report its quarter ended March 2026 results.

📅 Concentra Group is expected to release its earnings on May 7, targeting $0.35 per share in EPS.

💰 Concentra Group's projected revenue is $554.26 million, representing a 10.7% increase year-over-year.

🔍 Investors can track future stock performance by monitoring trends in earnings estimate revisions.

Bullish Signals
  • Cencora delivered earnings of $4.75 per share for the quarter ended March 2026, which compares favorably to last year's $4.42 per share despite missing consensus by a small margin.
  • The company has topped consensus revenue estimates two times over the last four quarters, demonstrating an ability to beat expectations periodically.
  • Cencora's revenues grew to $78.36 billion from the year-ago level of $75.45 billion, showing consistent top-line growth.
  • The Zacks Medical Services industry is currently ranked in the top 39% of all Zacks-ranked industries, placing Cencora in a strong relative position that historically outperforms the bottom half by a factor of more than 2 to 1.
  • Competition remains robust within the sector as peer Concentra Group Holdings Parent (CON) expects significant growth with projected earnings of $0.35 per share and revenues rising 10.7% in its upcoming March quarter report.
  • Investors can access Zacks Investment Research's comprehensive analysis, including a list of today's top-ranked stocks to identify further upside potential.
Risk Factors
  • Cencora reported Q2 earnings of $4.75 per share, missing the Zacks Consensus Estimate of $4.8 per share by -1.04%.
  • The company posted revenues of $78.36 billion for the quarter ended March 2026, falling short of the consensus estimate by 2.98%.
  • Cencora shares have underperformed significantly this year, losing approximately 9.4% compared to the S&P 500's gain of 6%.
  • The stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform merely in line with the market rather than outperforming.
  • Investors face uncertainty regarding future earnings estimate revisions, which have historically correlated strongly with near-term stock price movements.
Full Analysis
Cencora (COR) reported Q2 2026 results that missed both earnings per share and revenue estimates. The company posted adjusted earnings of $4.75 per share, slightly below the Zacks Consensus Estimate of $4.80, marking a negative earnings surprise of -1.04%. Revenue for the quarter ended March 2026 was $78.36 billion, which fell short of the estimated $80.61 billion by 2.98%. Year-over-year growth saw earnings increase to $4.75 from $4.42 a year prior, while revenue climbed from $75.45 billion. This marks the second consecutive quarter of missing estimates after beating them three times in the previous four quarters. Despite the miss, Cencora's stock underperformed the broader market, declining approximately 9.4% year-to-date compared to the S&P 500's gain of 6%. The article notes that future price movements will largely hinge on management's commentary during the earnings call and subsequent trends in analyst estimates. Currently, the mixed estimate revisions ahead of the report have translated Cencora into a Zacks Rank #3 (Hold), suggesting the stock may perform in line with the market until consensus forecasts are updated. Looking ahead, the consensus EPS estimate for the coming quarter is set at $4.35 on projected revenues of $87.24 billion, while the full-year fiscal year consensus stands at $17.58 per share on $346.07 billion in revenue. The analysis highlights that the medical services industry as a whole remains in the top 39% of Zacks-ranked industries, which historically outperforms the bottom half by a factor of more than 2 to 1. The report also mentions peer Concentra Group (CON) is set to report its own Q2 results on May 7 with expectations of $0.35 in earnings and revenues exceeding $554 million.